Skip to main content
Equibles
PTIX logo

PTIX · Protagenic Therapeutics, Inc.\new

Track PTIX — free

Use PTIX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.57 -0.17 (-22.97%) At close · Jan 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The Company expects that additional capital may be required during the next 12 months to continue executing its business plan and to meet its obligations as they become due. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed Aug 19, 2026
Market Cap
$1.45M
Shares
1.81M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.57 Open$0.32 Day$0.26–0.61 Since split$0.57–11.10 Avg vol 30d172K Short int13K · 0.7% float · 1.0d Short vol29% Last earningsMar 31, 2023 DataMay 2025–Jan 2026 Filing10-Q · Aug 19

Raw chart and full-history price indicators begin at the captured split on May 5, 2025; bars on opposite sides are not compared.

The closing range begins at the captured split on May 5, 2025.

Up next

FQ2-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 19, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −70%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −66%
trailing
6-month return −84%
trailing
YTD return −56%
this year
Relative strength −94%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-50% holders QoQ
Insider flow Accumulating
Net +$30.7K over 90 days · 0% sells
Short interest Rising
0.73% of float · ▲ +0.1% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Fundamentals
Fair
EPS growth +188%
Y/Y
Free cash flow $-2.8M
Quant / Vol
risk profile
Very High
Volatility 365%
annualized · 1-yr
Max drawdown −95%
past year
ATR 38.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−70% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-50% holders QoQ
Insider flow Accumulating
Net +$30.7K over 90 days · 0% sells
Short interest Rising
0.73% of float · ▲ +0.1% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its range since split · 2025-05-05
Range low $1 Now $1 · 0% Range high $11
vs 50-day avg -70%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PTIX
Protagenic Therapeutics, Inc.\new
this stock
$1.45M -56.2% — — 0.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +6.7% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +423.1% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
3.7%
Net QoQ
-117 sh
Top holder
DRW Securities, LLC
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
13.2K
Days to cover
1.0d
Change
+9 sh
View
Short Volume
Short vol %
29%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
52
Value
$32
As of
May 22, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jan 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$30.7K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$1.4M
EPS diluted
$0.59
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 20, 2026
This year
8
View
Earnings & Events
Earnings Calls
Last call
Mar 31, 2023
View

Performance

Raw-price comparisons begin at the captured split on May 5, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
PTIX -57.0% -66.1% -83.6% -56.2% -56.2%
SPY -0.4% +0.5% +10.5% +0.9% +0.9%
vs SPY -56.6% -66.6% -94.2% -57.0% -57.0%
Key facts CIK 1022899 CUSIP 74365N301 13F (30d) 1 filings 1 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)